Alzheimer's Disease Trial, Not Yet Recruiting NCT06868030 Sponsor: First Hospital of China Medical University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Not Yet Recruiting

NCT06868030
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged between 50 and 85 years old, either male or female.
  • People who have completed at least primary school education, have normal hearing, vision, and speech, speak Mandarin as their daily language, and are able to complete the information collection required by the study.
  • People who have been diagnosed with Alzheimer's disease (AD) or mild cognitive impairment (MCI) according to specific recognised diagnostic guidelines (confirm with trial site for exact criteria).
  • People who have had amyloid deposits (a protein buildup associated with Alzheimer's disease) confirmed through brain imaging or cerebrospinal fluid (fluid around the brain and spine) testing.
  • People who have cognitive (thinking and memory) decline and meet at least one of the following: a score of 20 or above on the MMSE memory test, or a score of 0.5 or 1 on the CDR-GS scale (both are standard tools doctors use to measure thinking and memory ability).
  • People in the combination treatment group who meet the specific eligibility requirements for the drug cainumab, as set out in the drug's official guidelines.
  • People who are willing and able to complete all study requirements, including MRI scans, thinking and memory assessments, and genetic testing.
  • People who have an established carer or family member who can objectively complete clinical assessments about their daily functioning and quality of life.
  • People (and their family members) who have been fully informed about the study and have signed a consent form agreeing to take part.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have other neurological (brain or nervous system) conditions that could affect brain function, such as depression, brain tumours, Parkinson's disease, encephalitis, epilepsy, multiple sclerosis, brain injury, or certain types of fluid build-up in the brain.
  • People who have other body-wide illnesses that could affect thinking and memory, such as liver or kidney problems, thyroid disorders, severe anaemia, vitamin deficiencies, syphilis, HIV, or a history of alcohol or drug misuse.
  • People who have serious or unstable health conditions affecting the heart, liver, kidneys, digestive system, lungs, hormones, immune system, blood, or other areas — or any condition the study doctor believes could affect the study results — or people whose life expectancy is less than 24 months.
  • People with a history of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder (note: people with a history of major depression may still be considered if no episodes have occurred or the condition has been controlled in the past year); people considered at risk of suicide; or people with a history of alcohol or substance misuse or dependence in the past 2 years.
  • People with severe stroke-related disability (confirm with trial site for exact scoring criteria) or a previous history of significant stroke.
  • People whose immune system is significantly affected by long-term use of immunosuppressive (immune-suppressing) medications.
  • People who are unable to have an MRI scan or have a medical reason preventing it, including but not limited to having a pacemaker not compatible with MRI, certain implants in the eyes, skin, or ears, an artificial heart valve, external metal implants, or any other condition that could make an MRI unsafe.
  • People who have had an allergic reaction to any ingredient in the study treatments, including the drug cincainizumab.
  • People who refuse to sign the informed consent form.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

If you need support right now

This page includes language about suicide and self-harm, because that is how the trial's eligibility criteria are written. If reading it has been hard, you do not have to keep going. The services below are free, confidential, and answered by people trained for exactly this.

If you or someone else is in immediate danger, call 000.

  • Lifeline — 24/7 crisis support: 13 11 14
  • Suicide Call Back Service — 24/7 counselling: 1300 659 467
  • 13YARN — 24/7, for Aboriginal and Torres Strait Islander people: 13 92 76
  • Beyond Blue — 24/7 mental health support: 1300 22 4636
  • Emergency: 000

Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention. If you are in immediate danger, call your local emergency number.

Voxsanity is not a crisis service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.

If this is close to home

This page includes language about advanced illness, prognosis, or palliative care, because that is how the trial's eligibility criteria are written. Seeing it set out plainly can land hard, whether it is about you or about someone you are caring for. You do not have to be at a crisis point to talk to someone.

  • Griefline — grief and loss counselling, 9am to 6pm weekdays and midday to 6pm weekends (AEST/AEDT): 1300 845 745
  • Carer Gateway — practical and emotional support if you are caring for someone, 8am to 5pm weekdays: 1800 422 737
  • Canteen — for 12 to 25 year olds affected by cancer, their own or a family member's: 1800 945 215
  • Palliative Care Australia — directory of palliative care services near you: palliativecare.org.au
  • Lifeline — 24/7, for any kind of distress, at any hour the services above are closed: 13 11 14

Palliative care is not the same as giving up on treatment, and it is not only for the last weeks of life. It is symptom and comfort care that can run alongside active treatment, including a clinical trial.

Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of support and crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention.

Voxsanity is not a counselling or medical service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.

Contact this trial

Principal Investigator: Huayan Liu, the first affiliated hospital of China medical university, neurology department

Phone: +86 13609831417

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
First Hospital of China Medical University
Registry
ClinicalTrials.gov
Start date
1 April 2025
Est. completion
31 December 2026

Primary endpoints

Efficacy and safety of conventional symptomatic drugs combined with lencanizumab in the treatment of early Alzheimer's disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov